Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.
View / Open Files
MetadataShow full item record
Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reuterswärd, C., Häkkinen, J., Degasperi, A., et al. (2019). Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.. Nature medicine, 25 (10), 1526-1533. https://doi.org/10.1038/s41591-019-0582-4
Whole genome sequencing (WGS) brings comprehensive insights to cancer genome interpretation. To explore clinical value of WGS, we sequenced 254 triple negative breast cancers (TNBC) with associated treatment and outcome data collected between 2010-2015 via the population-based Sweden Cancerome Analysis Network-Breast (SCAN-B) project (ClinicalTrials.gov ID:NCT02306096). Applying the HRDetect mutational-signature-based algorithm to classify tumors, 59% were predicted to have Homologous-recombination-repair deficiency (HRDetect-high): 67% explained by germline/somatic mutations of BRCA1/BRCA2, BRCA1 promoter hypermethylation, RAD51C hypermethylation or biallelic loss of PALB2. A novel mechanism of BRCA1 abrogation was discovered via germline SINE-VNTR-Alu retrotransposition. HRDetect provided independent prognostic information, with HRDetect-high patients having better outcome on adjuvant chemotherapy for invasive disease-free survival (Hazard Ratio, HR=0.42, 95% confidence interval, CI=0.2-0.87), and distant relapse-free interval (HR=0.31, CI=0.13-0.76) compared to HRDetect-low, regardless of whether a genetic/epigenetic cause was identified. HRDetect-intermediate, some possessing potentially targetable biological abnormalities, had poorest outcomes. HRDetect-low cancers also had inadequate outcomes: ~4.7% were mismatch-repair-deficient - another targetable defect, not typically sought; and was enriched for (but not restricted to) PIK3CA/AKT1 pathway abnormalities. New treatment options need to be considered for now-discernible HRDetect-intermediate and HRDetect-low categories. This population-based study advocates for WGS of TNBC to better inform trial stratification and improve clinical decision-making.
Humans, Neoplasm Recurrence, Local, Prognosis, Disease-Free Survival, Genetics, Population, DNA Methylation, Germ-Line Mutation, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Promoter Regions, Genetic, Triple Negative Breast Neoplasms, Whole Genome Sequencing
Cancer Research UK (23916)
Cancer Research UK (25274)
Cancer Research UK (23433)
External DOI: https://doi.org/10.1038/s41591-019-0582-4
This record's URL: https://www.repository.cam.ac.uk/handle/1810/296705